Table 2.
Treatment outcomes
| Determinant | Anterior tumour | Posterior tumour | p value | ||
|---|---|---|---|---|---|
| Median/mean/N | IQR/range/% | Median/mean/N | IQR/range/% | ||
| Total patients, N | 45 | 222 | |||
| Recurrences in treated area, N, (%) | 17 | 37.8% | 45 | 20.3% | 0.019 |
| Proof of recurrence by | |||||
| Biopsy, N, (% of recurrences) | 8 | 47% | 22 | 49% | 0.930 |
| mpMRI, N, (% of recurrences) | 9 | 53% | 23 | 51% | 1.074 |
| Time to recurrence (mth), mean, (range) | 28.5 | 22–41 | 21 | 18–36 | 0.274 |
| Follow-up without recurrence (mth), mean, (range) | 29 | 15.5–46 | 19 | 11–41 | 0.030 |
| Secondary treatment modality | |||||
| Secondary HIFU, N, (% of recurrences) | 9 | 53% | 39 | 87% | |
| Cryoablation, N, (% of recurrences) | 6 | 35% | 0 | 0% | |
| Radical prostatectomy, N, (% of recurrences) | 1 | 6% | 5 | 11% | |
| Radiotherapy, N, (% of recurrences) | 1 | 6% | 1 | 2% | |
N number, IQR inter quartile range, mpMRI multiparametric MRI, mth month, ADT androgen deprivation therapy